![McKesson Corporation Website](https://cdn.finchat.io/288195.png)
McKesson Corporation
NYSE-MCK
Company Overview
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Name
McKesson Corporation
CEO
Mr. Brian S. Tyler Ph.D.
Website
www.mckesson.com
Sector
Health Care Providers and Services
Year Founded
1833
Profile
Market Cap
$65.38B
EV
$70.89B
Shares Out
129.68M
Revenue
$313.75B
Employees
48,000
Margins
Gross
4.05%
EBITDA
1.64%
Operating
1.47%
Pre-Tax
1.21%
Net
0.94%
FCF
1.12%
Returns (5Yr Avg)
ROA
1%
ROTA
-158.21%
ROE
-93.91%
ROCE
22.28%
ROIC
14.97%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
$619.53
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
$2,302M
Net Debt
$5,134M
Debt/Equity
-5.38
EBIT/Interest
16.43
Growth (CAGR)
Rev 3Yr
8.56%
Rev 5Yr
7.61%
Rev 10Yr
7.76%
Dil EPS 3Yr
-7.58%
Dil EPS 5Yr
48.63%
Dil EPS 10Yr
15.41%
Rev Fwd 2Yr
11.31%
EBITDA Fwd 2Yr
9.97%
EPS Fwd 2Yr
14.26%
EPS LT Growth Est
12.02%
Dividends
Yield
—
Payout
11.04%
DPS
$2.48
DPS Growth 3Yr
13.86%
DPS Growth 5Yr
9.71%
DPS Growth 10Yr
9.96%
DPS Growth Fwd 2Yr
9.87%